Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new post hoc sub-analysis of the randomized evaluation of long term anticoagulant therapy (RE-LY) trial by Boehringer Ingelheim found Pradaxa (dabigatran etexilate) 150mg bid reduced the risk of stroke compared to well-controlled warfarin in patients with non-valvular atrial fibrillation (AF) and symptomatic heart failure (sHF).
Subscribe to our email newsletter
Pradaxa, an oral anticoagulant, has been approved for the prevention of stroke in AF in more than 50 countries across the globe.
RE-LY was a global, Phase III, prospective, randomized, open-label with blinded endpoint evaluation (PROBE) trial of 18,113 patients, which compared two fixed doses of the oral direct thrombin inhibitor dabigatran (110mg and 150mg bid) each administered in a blinded manner, with well controlled (INR 2.0-3.0, median TTR 67%1) open label warfarin.
The data showed that the rates of intracranial bleeding were lower with both doses of Pradaxa compared to well-controlled warfarin, irrespective of whether patients had sHF or not.
In addition, annual rates of stroke or systemic embolism were higher overall for patients with sHF (Pradaxa 110mg bid: 1.90%, Pradaxa® 150mg bid: 1.44%, warfarin: 1.92%) than those without sHF (Pradaxa 110mg bid: 1.41%, Pradaxa®150mg bid: 1.00%, warfarin: 1.64%).